Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase NA 20Phase 1 18Phase EARLY_PHASE1 5Phase 1/2 4Phase 2/3 1

Status

Recruiting 40Active not recruiting 18Completed 9Not yet recruiting 7Withdrawn 4Terminated 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Uveal Melanoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Magnetic Resonance Spectroscopy × Clear all
NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
Dermatologic

Uveal Melanoma

NCT00471835 2017-01-19

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Wake Forest University Health Sciences

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡